Swiss biopharma company ObsEva and Japanese company Kissei Pharmaceutical have joined forces to develop and commercialize KLH-2109 for the treatment of endometriosis and other potential indications, it has been announced.
KLH-2109 is an oral, gonadotropin-releasing hormone (GnRH) antagonist, for which three Phase 2a studies have been completed in endometriosis in Japan.
Under the terms of the agreement, ObsEva will acquire the exclusive rights to develop and commercialize KLH-2109 worldwide, excluding Asia. Both companies will collaborate in parallel on the development of KLH-2109, referred to as OBE2109 in ObsEva’s pipeline.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze